
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight is poised for success as they continue to implement their commercial strategy and see improvements in their utilization rates and quarterly placements. The company's revenue beat consensus and management is confident in their guidance for achieving $120-135M in revenue in 2026. With the potential for faster LDD installed base growth, higher utilization, and margin improvement, there is potential for upside. Though there are risks, such as limited adoption and competition in the IOL market, the undemanding valuation and achievable guidance make RxSight a solid buy.
Bears say
RxSight is facing significant challenges and risks that may hinder its ability to achieve future growth and profitability. These include limited adoption of its light-adjustable lenses due to the need for an additional piece of capital equipment, disappointing commercial execution, increased competition in the intraocular lens market, and potential for dilutive financing rounds. The company's most recent financial guidance for 2026 was below market expectations for revenue and gross margin, and the company also expects to continue investing in operating expenses, potentially impacting profitability.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares